Company registration number 15576556 (England and Wales)
HEYBRIDGE PHARMA LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 NOVEMBER 2025
PAGES FOR FILING WITH REGISTRAR
HEYBRIDGE PHARMA LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 7
HEYBRIDGE PHARMA LIMITED
BALANCE SHEET
AS AT
30 NOVEMBER 2025
30 November 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Intangible assets
3
548,212
-
0
Tangible assets
4
23,545
-
0
571,757
-
0
Current assets
Stocks
31,917
-
Debtors
5
148,240
-
0
Cash at bank and in hand
120,196
100
300,353
100
Creditors: amounts falling due within one year
6
(397,686)
-
0
Net current (liabilities)/assets
(97,333)
100
Total assets less current liabilities
474,424
100
Creditors: amounts falling due after more than one year
7
(377,007)
-
0
Provisions for liabilities
(5,178)
-
Net assets
92,239
100
Capital and reserves
Called up share capital
100
100
Profit and loss reserves
92,139
-
0
Total equity
92,239
100
HEYBRIDGE PHARMA LIMITED
BALANCE SHEET (CONTINUED)
AS AT
30 NOVEMBER 2025
30 November 2025
- 2 -

For the financial year ended 30 November 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

T he members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved and signed by the director and authorised for issue on 1 May 2026
Mr CP Patel
Director
Company registration number 15576556 (England and Wales)
HEYBRIDGE PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 NOVEMBER 2025
- 3 -
1
Accounting policies
Company information

Heybridge Pharma Limited is a private company limited by shares incorporated in England and Wales. The registered office is 13 Larchwood Avenue, Romford, RM5 2QL.

1.1
Reporting period

These financial statements cover the twelve‑month period ended 30 November 2025. The comparative figures relate to a dormant period of eight months and eleven days ended 30 November 2024. Accordingly, the results for the current period are not directly comparable with those of the prior period.

1.2
Basis of preparation

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.3
Going concern

A true t the time of approving the financial statements, t he director has a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus t he director continues to adopt the going concern basis of accounting in preparing the financial statements.

1.4
Revenue

Revenue comprises sales of goods or services provided to customers net of value added tax and other sales taxes, less an appropriate deduction for actual and expected returns and discounts. Revenue is recognised when performance obligations are satisfied and the control of goods or services is transferred to the buyer. Where the performance obligation is satisfied over time, revenue is recognised in accordance with its progress towards complete satisfaction of that performance obligation.

When cash inflows are deferred and represent a financing arrangement, the promised consideration is adjusted for the effects of the time value of money, which is recognised as interest income.

The nature, timing of satisfaction of performance obligations and significant payment terms of the company's major sources of revenue are as follows:

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

HEYBRIDGE PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 NOVEMBER 2025
1
Accounting policies
(Continued)
- 4 -
1.5
Intangible fixed assets - goodwill

Goodwill represents the excess of the cost of acquisition of unincorporated businesses over the fair value of net assets acquired. It is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is considered to have a finite useful life and is amortised on a systematic basis over its expected life, which is 20 years.

For the purposes of impairment testing, goodwill is allocated to the cash-generating units expected to benefit from the acquisition. Cash-generating units to which goodwill has been allocated are tested for impairment at least annually, or more frequently when there is an indication that the unit may be impaired. If the recoverable amount of the cash-generating unit is less than the carrying amount of the unit, the impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the unit and then to the other assets of the unit pro-rata on the basis of the carrying amount of each asset in the unit.

1.6
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Leasehold land and buildings
Over the lease term
Fixtures and fittings
20% on reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.7
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.8
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.9
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

HEYBRIDGE PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 NOVEMBER 2025
1
Accounting policies
(Continued)
- 5 -
Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.10
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.11
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
6
1
HEYBRIDGE PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 NOVEMBER 2025
- 6 -
3
Intangible fixed assets
Goodwill
£
Cost
At 1 December 2024
-
0
Additions
577,065
At 30 November 2025
577,065
Amortisation and impairment
At 1 December 2024
-
0
Amortisation charged for the year
28,853
At 30 November 2025
28,853
Carrying amount
At 30 November 2025
548,212
At 30 November 2024
-
0
4
Tangible fixed assets
Leasehold land and buildings
Fixtures and fittings
Total
£
£
£
Cost
At 1 December 2024
-
0
-
0
-
0
Additions
3,034
25,891
28,925
At 30 November 2025
3,034
25,891
28,925
Depreciation and impairment
At 1 December 2024
-
0
-
0
-
0
Depreciation charged in the year
202
5,178
5,380
At 30 November 2025
202
5,178
5,380
Carrying amount
At 30 November 2025
2,832
20,713
23,545
At 30 November 2024
-
0
-
0
-
0
HEYBRIDGE PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 NOVEMBER 2025
- 7 -
5
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
102,398
-
0
Other debtors
33,568
-
0
Prepayments and accrued income
12,274
-
0
148,240
-
6
Creditors: amounts falling due within one year
2025
2024
£
£
Bank loans
17,360
-
0
Trade creditors
145,495
-
0
Taxation and social security
39,438
-
0
Other creditors
195,393
-
0
397,686
-
0
7
Creditors: amounts falling due after more than one year
2025
2024
Notes
£
£
Bank loans and overdrafts
377,007
-
0
Creditors which fall due after five years are payable as follows:
Payable by instalments
331,074
-

The bank loan falling due within one year and after more than one year is secured by a fixed and floating charge over the assets of the company.

The following assets have been charged as security to Lloyds Bank Plc:

1) An unlimited debenture granted by Heybridge Pharma Limited in favour of Lloyds Bank Plc, creating a fixed and floating charge over the assets of the company.

2) A first legal charge over the land and buildings situated at Units 10a / 10b Bentalls Shopping Centre, Colchester Road, Heybridge, Maldon, CM9 4GD, granted by Heybridge Pharma Limited in favour of Lloyds Bank Plc.

3) An all‑monies guarantee from Mr C Patel for a principal amount of £80,000, together with interest and associated costs, in respect of the company’s liabilities to Lloyds Bank Plc.

2025-11-30 2024-12-01 false false false 01 May 2026 CCH Software CCH Accounts Production 2026.100 No description of principal activity Mr CP Patel 15576556 2024-12-01 2025-11-30 15576556 2025-11-30 15576556 2024-11-30 15576556 core:Goodwill 2025-11-30 15576556 core:Goodwill 2024-11-30 15576556 core:FurnitureFittings 2025-11-30 15576556 core:LandBuildings 2024-11-30 15576556 core:FurnitureFittings 2024-11-30 15576556 core:CurrentFinancialInstruments core:WithinOneYear 2025-11-30 15576556 core:CurrentFinancialInstruments core:WithinOneYear 2024-11-30 15576556 core:Non-currentFinancialInstruments core:AfterOneYear 2025-11-30 15576556 core:Non-currentFinancialInstruments core:AfterOneYear 2024-11-30 15576556 core:CurrentFinancialInstruments 2025-11-30 15576556 core:CurrentFinancialInstruments 2024-11-30 15576556 core:ShareCapital 2025-11-30 15576556 core:ShareCapital 2024-11-30 15576556 core:RetainedEarningsAccumulatedLosses 2025-11-30 15576556 core:RetainedEarningsAccumulatedLosses 2024-11-30 15576556 bus:Director1 2024-12-01 2025-11-30 15576556 core:Goodwill 2024-12-01 2025-11-30 15576556 core:LandBuildings core:LongLeaseholdAssets 2024-12-01 2025-11-30 15576556 core:FurnitureFittings 2024-12-01 2025-11-30 15576556 2024-03-19 2024-11-30 15576556 core:Goodwill 2024-11-30 15576556 core:Goodwill core:ExternallyAcquiredIntangibleAssets 2024-12-01 2025-11-30 15576556 core:LandBuildings core:LeasedAssetsHeldAsLessee 2024-11-30 15576556 core:FurnitureFittings 2024-11-30 15576556 2024-11-30 15576556 core:LandBuildings core:LeasedAssetsHeldAsLessee 2025-11-30 15576556 core:LandBuildings core:LeasedAssetsHeldAsLessee 2024-12-01 2025-11-30 15576556 core:Non-currentFinancialInstruments 2025-11-30 15576556 core:Non-currentFinancialInstruments 2024-11-30 15576556 bus:PrivateLimitedCompanyLtd 2024-12-01 2025-11-30 15576556 bus:SmallCompaniesRegimeForAccounts 2024-12-01 2025-11-30 15576556 bus:FRS102 2024-12-01 2025-11-30 15576556 bus:AuditExemptWithAccountantsReport 2024-12-01 2025-11-30 15576556 bus:FullAccounts 2024-12-01 2025-11-30 xbrli:pure xbrli:shares iso4217:GBP